Why is Mesoblast (ASX: MSB) on investors’ radar

 

Highlights

  • COVID-19 ARDS stemming from COVID-19 infection is a leading cause of death among COVID-19 patients.
  • Mesoblast Limited (ASX: MSB) is developing and testing remestemcel-L for reducing the mortality occurring due to COVID-19 ARDS in adults.
  • As a next step, the company is expected to resubmit the current Biologic License Application (BLA) with a six-month review period.


Rising coronavirus cases are increasing, posing a grave threat, especially in Queensland and Western Australia, as the number of cases topped 800 in the past few days.

However, with the surge in COVID-19 cases, diseases or symptoms arising from the infection also take a toll on humans. For example, In COVID-19 ARDS (Acute Respiratory Distress Syndrome), the organs are deprived of oxygen as the air-sacs of the lungs are filled with fluids. ARDS has been identified as the leading reason for death for ventilator-dependent COVID-19 patients.

Mesoblast Limited (ASX: MSB) is an Australian biopharmaceutical company that has developed remestemcel-L for reducing the mortality occurring due to COVID-19 ARDS in adults.

Related Article: Why are Mesoblast (ASX:MSB) shares worth watching today?

What is the latest update on remestemcel-L?

Mesoblast, a global leader in off-the-shelf cell medicines, announced 90-day survival outcomes of the remestemcel-L trial that was conducted on 222 patients suffering from moderate to severe COVID-19 ARDS.

The results indicated that the two doses of remestemcel-L reduce the death rate by 48% in 90 days, and the 60 days results showed a reduction by 46%.

When remestemcel-L was used along with the dexamethasone, then the mortality benefits reported were 77% in the case of the patients under the age of 65.

Mesoblast has signed a collaboration and licence agreement with Novartis for the manufacturing, development and commercialisation of the dose and giving special consideration to the COVID-19 ARDS patients.

Related Article: Mesoblast (ASX:MSB) reveals results from Phase 3 trial for Chronic Low Back Pain

On July 30, MSB announced that they met with FDA (United States Food and Drugs Administration) to make a progress in getting regulatory approvals for the product, remestemcel-L. As a next step, Mesoblast should discuss with FDA’s Center for Biologics Evaluation and Research’s (CBER) review team to sort out certain outstanding chemistry, manufacturing and controls (CMC) items that will support resubmission of the current Biologic License Application (BLA) with a six-month review period.

Image source: © Robig | Megapixl.com

RELATED ARTICLE: ASX Indices Took Support From Global Indices

Bottom Line

MSB is on investors’ radar as the company is in the process of successfully treating ARDS, one of the leading reasons for death due to COVID-19.

MSB shares closed at AU$1.935 with a market capitalisation of AU$1.20 billion. 



Location: Australia

Popular posts from this blog

Beginners Guide to Penny Stocks

  What Are Penny Stocks? Penny stocks  are stocks with lower market capitalisation relative to the other companies; primarily, these are new companies in the publicly traded market. Alternatively, penny stocks are also identified as micro-cap stocks and nano-cap stocks in the US market. As an example, we can look at the metals & mining sector in Australia. Lately, the animal spirit in the sector have been propelling investments, and a lot of development has taken place in the past two-three years. As a result of this, mining services companies have also gained traction, and revenue of these ancillary services companies to mining business has gone up. Ausdrill Limited  ( ASX: ASL )  a mining services company, recently on 29 August 2019, released its full-year results closed 30 June 2019. Interestingly, the revenue of the company witnessed a growth of 89.1% over the previous year attributing to escalated business opportunities. Check How to Buy Penny Stocks and its...
Read more

Two ASX-listed resource stocks under the spotlight today

Image
Summary The ASX resource index has gained more than 21% in the last one year. Vulcan Energy has achieved a lithium extraction target. The company plans to ramp up activities towards its goal of developing the world's first zero-carbon lithium project. De Grey Mining has extended gold mineralisation at the Hemi discovery in Western Australia. S&P/ ASX 200 Resources posted a jump of 1.122% or 59.7 points to settle the day’s trade at 5381.7 on 27 May 2021. The index has gone up by around 21.53% in the last one year. Price is Less albeit Opportunities are Immense; Invest Wise with Kalkine LITE Just at $19.99 Source: © Edhardream | Megapixl.com Today on the  ASX , two resource space players - Vulcan Energy Resources Limited ( ASX: VUL ) and De Grey Mining Limited ( ASX: DEG ) made key announcements. Vulcan updated on its lithium extraction piloting test work, while De Grey has extended gold mineralisation at its Hemi discovery. Interesting Read:  Six Major Gold Miners with Mas...
Read more

Seven ASX-listed shares priced under 80 cents

Image
  Summary Stocks priced under 80 cents fall under the penny stocks category. These highly volatile stocks can offer significant upside potential. Although an attractive option for risk-takers, risk-averse investors generally stay away from penny stocks, given the high volatility attached. Some of the high-performing stocks priced under 80 cents include In the current period of uncertain economic scenario, share prices are fluctuating at a higher rate. The fluctuations are apparent given the high volatility, primarily due to the COVID-19  pandemic . However, there are some low-priced stocks, called  penny stocks , that are affordable and offer a ray of hope given their potential to offer impressive returns. These stocks do carry significant risk and thus are not appealing for all market participants. Copyright © 2021 Kalkine Media This article would walk you through 7 ASX-listed shares priced below 80 cents. GOOD TO KNOW:  How do I start trading penny stocks in Austra...
Read more